期刊文献+

中原地区冠心病患者血脂谱调查与载脂蛋白ApoB/ApoAI比值的意义 被引量:5

Investigation of lipid profile and significance evaluation of ApoB/ApoAI ratio on coronary heart disease patients in central plains region of China
原文传递
导出
摘要 目的:通过分析中原地区冠心病患者血脂谱特征,探讨载脂蛋白B/载脂蛋白AI(ApoB/ApoAI)比值作为冠心病危险因素评估指标的必要性和优势。方法:冠状动脉造影确诊的正常对照组和冠心病患者,进行血脂及载脂蛋白生化分析,统计各血脂谱的相关性,比较各相关系数的差异。结果:①TC、LDL-C、non-HDL-C、ApoB、TC/HDL-C和ApoB/ApoAI各指标在冠心病组显著高于对照组(P<0.05)。②冠心病组HDL-C浓度在各水平分层的比例均明显低于对照组(P=0.002),而TC和LDL-C差异无统计学意义(P>0.05)。③LDL-C与non-HDL-C有最密切的相关性(r=0.959),两者与ApoB/ApoAI的相关性差异无统计学意义(P>0.05),而两者分别与ApoB/ApoAI的相关性与ApoB/ApoAI和ApoB、TC/HDL-C的相关性有显著差异(P<0.05)。结论:中原地区冠心病患者具有低HDL-C的特征,由于各血脂谱统计学相关性的显著差异,ApoB/ApoAI比值可能是反映此类患者心血管病风险的理想标志物和治疗靶点。 Objective:Through analyses of lipid profile on coronary heart disease patients in central plains region of china,we investigated whether the necessity and advantage of ApoB/ApoAI ratio could be a risk factor in coronary heart disease(CHD).Method:Serum lipid and apolipoprotein of control and CHD patients confirmed by coronary angiography were chemical analyzed.The percentage of different lipid levels divided by Chinese lipid guideline was investigated and compared by t test in two groups.Correlations of different lipid profile were analyzed statistically;and significant difference of correlation coefficient was compared through fisher z transformation.Result:①the value of Total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),non-high density liprotein cholesterol(non-HDL-C),apolipoprotein B(ApoB),TC/HDL-C ratio and ApoB/ApoAI ratio in coronary heart disease group were significant higher than those in control group(P0.05),while the concentration of triglyceride(TG) had no significant difference in two groups.The concentration of high density lipoprotein cholesterol(HDL-C) and apolipoprotein AI(ApoAI) were lower significantly than those in control group(P=0.003 and P=0.002,respectively).②the percentage of HDL-C in different levels in CHD groups had significant difference than those in control groups(P=0.002),while the percentage of TC and LDL-C in two groups were no significant difference(P0.05).③LDL-C and non-HDL-C had closest correlation(r=0.959),and two correlation coefficients of LDL-C with ApoB/ApoAI and non-HDL-C with ApoB/ApoAI were not significant different(P0.05).But these two indexes had significant difference,respectively,compared with the correlation coefficients of ApoB/ApoAI with ApoB and ApoB/ApoAI with TC/HDL-C(P0.05).Conclusion:The CHD patients in central plains region of China were characteristic of low HDL-C concentration.For the statistical difference among lipid profile,ApoB/ApoAI ratio would be ideal marker and therapy target in these patients.
出处 《临床心血管病杂志》 CAS CSCD 北大核心 2011年第6期426-429,共4页 Journal of Clinical Cardiology
关键词 冠心病 载脂蛋白ApoB/ApoAI 血脂谱 中原地区 coronary heart disease apolipoproteinApoB/ApoAI lipid profile central plains region of China
  • 相关文献

参考文献13

  • 1NATARAJAN P,RAY K K,CANNON C P.High-density lipoprotein and coronary heart disease:current and future therapies[J].J Am Coll Cardiol,2010,55:1283-1299.
  • 2WALLDIUS G,JUNGNER I.The apoB/apoA-I ratio:a strong,new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence[J].J Intern Med,2006,259:493-519.
  • 3KASTELEIN J J,AKDIM F,STROES E S,et al.Simvastatin with or without ezetimibe in familial hypercholesterolemia[J].N Engl J Med,2008,358:1431-1443.
  • 4NATARAJAN P,RAY K K,CANNON C P.High-density lipoprotein and coronary heart disease:current and future therapies[J].J Am Coll Cardiol,55,1283-1299.
  • 5CHEN X,WANG Y.Tracking of blood pressure from childhood to adulthood:a systematic review and meta-regression analysis[J].Circulation,2008,117:3171-3180.
  • 6LI Z,YANG R,XU G,XIA T.Serum lipid concentrations and prevalence of dyslipidemia in a large professional population in Beijing[J].Clin Chem,2005,51:144-150.
  • 7廖玉华,诸骏仁.适度调脂稳定和逆转冠状动脉粥样硬化斑块[J].临床心血管病杂志,2010,26(1):1-3. 被引量:19
  • 8PISCHON T,GIRMAN C J,SACKS F M,et al.Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men[J].Circulation,2005,112:3375-3383.
  • 9MARCOVINA S,PACKARD C J.Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels[J].J Intern Med,2006,259:437-446.
  • 10SCHARNAGL H,NAUCK M,WIELAND H,et al.The Friedewald formula underestimates LDL cholesterol at low concentrations[J].Clin Chem Lab Med,2001,39:426-431.

二级参考文献10

  • 1Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:345
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5224
  • 3TSI MIKAS S,,WILLEIT J,KNOFLACH M,et al.Lipoprotein-associated phospholipase A2activity,fer-ritin levels,metabolic syndrome,and10-year cardio-vascular and non-cardiovascular mortality:results fromthe Bruneck study[].European Heart Journal.2009
  • 4Jang IK,Tearney GL,MacNeill B,et al.In vivo character-ization of coronary atherosclerotic plaque by use of optical coherence tomography[].Circulation.2005
  • 5F.D. Kolodgie,A.P. Burke,K.S. Skorija.Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis[].Arteriosclerosis and Thrombosis.2006
  • 6MacPhee CH,Moores KE,Boyd HF,et al.Lipoprotein-associated phospho-lipase A2,platelet-activatingfactor acetylhydrolase,generatestwo bioactive prod-ucts duringthe oxidation of low-densitylipoprotein:use of a novel inhibitor[].Biochemistry.1999
  • 7Lavi,S.,McConnell,J.P.,Rihal,C.S.Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans[].Circulation.2007
  • 8M Persson,B Hedblad,JJ Nelson,G Berglund.Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects[].Arteriosclerosis and Thrombosis.2007
  • 9Marshall AC,Peter HJ,Michael HD.Reviewof the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2as a Cardiovascular Risk Marker[].The American Journal of Cardiolo-gy.2008
  • 10P. W. Serruys,H. M. Garcia-Garcia,P. Buszman,P. Erne,S. Verheye,M. Aschermann.Effects of the direct lipoprotein-associated phospholipase a(2) inhibitor darapladib on human coronary atherosclerotic plaque[].Circulation.2008

共引文献23

同被引文献53

  • 1林琳,刘明开,佟凤芝,黄敏.超敏C反应蛋白与冠状动脉粥样硬化疾病的研究进展[J].大连医科大学学报,2009,31(1):102-105. 被引量:43
  • 2勾蓝图,傅明德,徐燕华,颜丙玉,杨雨叶,杨鲁川.动脉粥样硬化低危与高危人群血清高密度脂蛋白亚类组成差异的研究[J].临床心血管病杂志,2004,20(9):559-561. 被引量:4
  • 3无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量:2058
  • 4柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2139
  • 5Reiner Z, Catapano A L, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) [J]. Eur Heart J, 2011,32(23) : 1769-1818.
  • 6Thygesen K, Alpert J S, White H D. Joint ESC/ACCF/AHA! WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction [J]. Eur Heart J, 2007,28(20) :2525-2538.
  • 7Walldius G, Jungner I. The apoB/apoA 1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid- lowering therapy-a review of the evidence [J]. J Intern Med, 2006,259(5) :493-519.
  • 8McGinnis B D, Olson K L, Delate T M, et al. Statin adherence and mortality in patients enrolled in a secondary prevention program [ J ]. Am J Manag Care, 2009,15 (10) : 689- 695.
  • 9KANNEL W B, WILSON P W. Efficacy of lipid pro files in prediction of coronary disease[J]. Am Heart J,1992,124:768-774.
  • 10The task force for the management of dyslipidaemiasof the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias[J]. Eur Heart J,2011,32:1769 1818.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部